SAN
DIEGO, July 25, 2023 /PRNewswire/ -- Illumina
Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and
array-based technologies, and Pillar Biosciences Inc., the pioneers
of Decision Medicine™, today announced a strategic partnership to
make Pillar's suite of oncology assays commercially available
globally as part of the Illumina portfolio of oncology products.
The agreement will result in an unprecedented offering of
complementary next-generation sequencing solutions that will
enhance the efficiency, accuracy, and cost-effectiveness of
oncology testing through advanced sequencing techniques, improving
patient access to personalized cancer treatment options.
"We are proud to partner with Pillar to provide products that
will improve care for patients with advanced and high-risk cancer,"
said Phil Febbo, chief medical
officer of Illumina. "By leveraging Pillar's targeted sequencing
technology alongside Illumina's state-of-the-art sequencing and
bioinformatics solutions, we will enable rapid and focused genomic
profiling of tumors, which is essential to facilitate personalized
therapy in healthcare systems across the globe."
Pillar's targeted assays help oncologists and researchers
identify mutations that drive tumor growth. This knowledge is
pivotal in making informed decisions about cancer treatment. By
gaining an understanding of the genomic landscape of the tumor,
clinicians can tailor treatment options such as targeted therapies
and immunotherapies to suit each patient's needs. This personalized
approach has the potential to result in more effective and precise
interventions.
"Pillar Biosciences is committed to enabling global access to
our high-value genomic profiling assays to empower better-informed
precision patient treatment," said Randy
Pritchard, CEO of Pillar Biosciences. "This agreement will
facilitate seamless integration between Pillar Biosciences assays
and Illumina sequencers, delivering a streamlined workflow and
complementary product offerings and leading to faster turnaround
times for patients."
Pillar's suite of oncology assays can be used on any of
Illumina's sequencers. Assay offering will depend on the region.
Commercial availability of Pillar's assays through Illumina is set
to begin this month.
Use of forward-looking statements
This release may contain forward-looking statements that involve
risks and uncertainties. Among the important factors to which
Illumina's business is subject that could cause actual results to
differ materially from those in any forward-looking statements are
challenges inherent in developing, manufacturing, and launching new
products and services, and Illumina's ability to successfully
partner with other companies and organizations to develop new
products, expand markets, and grow its business, together with
other factors detailed in Illumina's filings with the Securities
and Exchange Commission, including its most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. Illumina
undertakes no obligation, and does not intend, to update these
forward-looking statements, to review or confirm analysts'
expectations, or to provide interim reports or updates.
About Pillar Biosciences
Pillar Biosciences is the
leader in Decision Medicine™, which is the utilization of highly
accurate and sensitive next-generation sequencing (NGS) testing
technology to generate data that optimizes the selection of
precision therapies for cancer patients, from tumor profiling to
therapy selection and recurrence monitoring. Pillar's NGS testing
solutions, including the FDA-approved oncoReveal™ CDx pan-cancer
solid tumor IVD, are powered by its proprietary SLIMamp® and PiVAT®
technologies, and decentralize the testing process, reducing
diagnostic costs and improving access and efficiency of complex NGS
testing for clinicians, prescribers, and patients globally. The
company has more than 20 NGS testing kits available in IVD or RUO
formats, and several others in various stages of development,
including a comprehensive liquid biopsy assay and tumor-informed
MRD assay. Pillar Biosciences has operations in Natick, MA and Shanghai, China. For more information visit
pillarbiosci.com and connect with us on LinkedIn.
About Illumina
Illumina is improving human
health by unlocking the power of the genome. In 2023 we celebrate
25 years of innovation, which has established us as a global leader
in DNA sequencing and array-based technologies, serving customers
in the research, clinical, and applied markets. Our products are
used for applications in the life sciences, oncology, reproductive
health, agriculture, and other emerging segments. To learn
more, visit illumina.com and connect with us
on Twitter, Facebook, LinkedIn, Instagram, TikTok,
and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
David McAlpine
347-327-1336
PR@illumina.com
View original
content:https://www.prnewswire.com/news-releases/illumina-and-pillar-biosciences-partner-to-improve-access-to-personalized-cancer-treatment-options-301884595.html
SOURCE Illumina, Inc.